Bob More

Bob More brings over 20 years of life sciences investing experience.

Bob currently manages investments in and serves on the board of Affinivax, eGenesis, Qihan Biopharmaceuticals, Tyra Biosciences, and Vir Biotechnology (NASDAQ:VIR). He was a founding board member of the Kauffman Fellows Program and is on the board of BIO (Biotechnology Innovation Organization).

Before joining Alta, Bob was a Senior Advisor for the Bill and Melinda Gates Foundation. Prior to that, Bob spent 5 years as a General Partner at Frazier Healthcare Ventures and 13 years at Domain Associates. Bob managed successful investments in and served on the boards of Cartiva (acquired by Wright Medical), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Glaukos Corporation (NYSE: GKOS), IntraLase (acquired by Advanced Medical Optics), Neothetics (merged with Evofem), NovaCardia (acquired by Merck), Oceana Therapeutics (acquired by Salix Pharmaceuticals) and Proxima Therapeutics (acquired by Cytyc Corporation). Bob was also an investor in Clovis Oncology (NASDAQ: CLVS), Encoded Genomics and Zeltiq Aesthetics (acquired by Allergan).

He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.